It is possible that while the inhibition of PARP1 by PARP inhibitors may provide therapeutic efficacy in cancer, the simultaneous inhibition of PARP2 may result in toxicity via transcriptional dysregulation in normal tissues. Here, PARP1 is linked to cancer.